| [1] |
FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee[J]. Int J Gynecol Obstet, 2002, 77(3): 285-287.
|
| [2] |
Yarandi F, Mousavi A, Abbaslu F, et al. Five-day intravascular methotrexate versus biweekly actinomycin-D in the treatment of low-risk gestational trophoblastic neoplasia: a clinical randomized trial[J]. Int J Gynecol Cancer, 2016, 26(5): 971-976.
|
| [3] |
Brown J, Naumann RW, Seckl MJ, et al. 15 years of progress in gestational trophoblastic disease: scoring, standardization, and salvage[J]. Gynecol Oncol, 2017, 144(1): 200-207.
|
| [4] |
Li J, Li S, Yu H, et al. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: a network Meta-analysis[J]. Gynecol Oncol, 2018, 148(2): 247-253.
|
| [5] |
Braga A, Campos V, Filho JR, et al. Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma? [J]. Gynecol Oncol, 2018, 148(2): 239-246.
|
| [6] |
李洁，向阳. 低危妊娠滋养细胞肿瘤化疗现状及耐药发生相关因素[J]. 中国实用妇科与产科杂志，2015, 31(11): 1052-1054.
|
| [7] |
Biscaro A, Braga A, Berkowitz RS. Diagnosis, classification and treatment of gestational trophoblastic neoplasia[J]. Rev Bras Gynecol Obstet, 2015, 37(1): 42-51.
|
| [8] |
Verhoef L, Baartz D, Morrison S, et al. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC) [J]. Aust N Z J Obstet Gynaecol, 2017, 57(4): 458-463.
|
| [9] |
Lawrie TA, Alazzam M, Tidy J, et al. First-line chemotherapy in low-risk gestational trophoblastic neoplasia[J]. Cochrane Database Syst Rev, 2016, 6: CD007102.
|
| [10] |
Wong LC, Choo YC, Ma HK. Methotrexate with citrovorum factor rescue in gestational trophoblastic disease[J]. Am J Obstet Gynecol, 1985, 152(1): 59-62.
|
| [11] |
Khan F, Everard J, Ahmed S, et al. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects [J]. Br J Cancer, 2003, 89(12): 2197-2201.
|
| [12] |
Maestá I, Nitecki R, Horowitz NS, et al. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center experience [J]. Gynecol Oncol, 2018, 148(1): 161-167.
|
| [13] |
Miller CR, Chappell NP, Sledge C, et al. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174？[J]. Gynecol Oncol, 2017, 144(1): 125-129.
|
| [14] |
Chapman-Davis E, Hoekstra AV, Rademaker AW, et al. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy[J]. Gynecol Oncol, 2012, 125(3): 572-575.
|
| [15] |
Osborne RJ, Filiaci V, Schink JC, et al. Phase Ⅲ trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2011, 29(7): 825-831.
|
| [16] |
Hasanzadeh M, Tabari A, Homae F, et al. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia[J]. J Cancer Res Ther, 2014, 10(3): 646-50.
|
| [17] |
Goldstein DP, Berkowitz RS, Horowitz NS. Optimal management of low-risk gestational trophoblastic neoplasia[J]. Exp Rev Anticancer Ther, 2015, 15(11): 1293-1304.
|
| [18] |
Lee YJ, Park JY, Kim DY, et al. Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease[J]. Gynecol Oncol, 2017, 28(2): e8.
|
| [19] |
范辰辰，冯冠芝，向阳，等. 放线菌素D单日冲击疗法治疗低危妊娠滋养细胞肿瘤[J]. 协和医学杂志，2017, 8(1): 25-29.
|
| [20] |
Mu X, Song L, Li Q, et al. Comparison of pulsed actinomycin D and 5-day actinomycin D as first-line chemotherapy for low-risk gestational trophoblastic neoplasia[J]. Int J Gynecol Obstet, 2018, 143(2): 225-231.
|
| [21] |
Hertz R, Li MC, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma[J]. Proc Soc Exp Biol Med, 1956, 93(2): 361-366.
|
| [22] |
Ross GT, Stolbach LL, Hertz R. Actinomycin D in the treatment of methotrexate-resistant trophoblastic disease in women[J]. Cancer Res, 1962, 22(8): 1015-1017.
|
| [23] |
Froeling FE, Seckl MJ. Gestational trophoblastic tumours: an update for 2014[J]. Curr Oncol Report, 2014, 16(11): 408.
|
| [24] |
Matsui H, Suzuka K, Yamazawa K, et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy[J]. Gynecol Oncol, 2005, 96(3): 616-620.
|
| [25] |
Alazzam M, Tidy J, Hancock BW, et al. First-line chemotherapy in low-risk gestational trophoblastic neoplasia[J]. Cochrane Database Syst Rev, 2012, 7: CD007102.
|
| [26] |
Taylor F, Grew T, Everard J, et al. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid[J]. Eur J Cancer, 2013, 49(15): 3184-3190.
|
| [27] |
Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009[J]. Br J Cancer, 2012, 107(11): 1810-1814.
|
| [28] |
Eiriksson L, Wells T, Steed H, et al. Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia[J]. Gynecol Oncol, 2012, 124(3): 53-557.
|
| [29] |
Chapman-Davis E, Hoekstra AV, Rademaker AW, et al. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy[J]. Gynecol Oncol, 2012, 125(3): 572-575.
|
| [30] |
Mousavi AS, Zamani A, Khorasanizadeh F, et al. Resistance to single-agent chemotherapy and its risk factors in low-risk gestational trophoblastic neoplasms[J]. J Obstet Gynaecol Res, 2015, 41(5): 776-783.
|
| [31] |
Garner EI, Feltmate CM, Goldstein DP, et al. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey[J]. Gynecol Oncol, 2005, 99(1): 3-5.
|
| [32] |
Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease[J]. Gynecol Oncol, 2004, 95(3): 423-429.
|
| [33] |
van Trommel NE, Massuger LF, Verheijen RH, et al. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey[J]. Gynecol Oncol, 2005, 99(1): 6-13.
|
| [34] |
Yarandi F, Jafari F, Shojaei H, et al. Clinical response to a second uterine curettage in patients with low-risk gestational trophoblastic disease a pilot study[J]. J Reprod Med, 2014, 59(11-12): 566-570.
|
| [35] |
Osborne RJ, Filiaci VL, Schink JC, et al. Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia[J]. Obstet Gynecol, 2016, 128(3): 535-542.
|
| [36] |
Ayatollahi H, Yekta Z, Afsari E. A pilot randomized controlled clinical trial of second uterine curettage versus usual care to determine the effect of re-curettage on patients′ need for chemotherapy among women with low risk, nonmetastatic gestational trophoblastic neoplasm in Urmia, Iran[J]. Int J Womens Health, 2017, 9: 665-671.
|
| [37] |
Eysbouts YK, Massuger LFAG, IntHout J, et al. The added value of hysterectomy in the management of gestational trophoblastic neoplasia[J]. Gynecol Oncol, 2017, 145(3): 536-542.
|
| [38] |
Bolze PA, Mathe M, Hajri T, et al. First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive[J]. Gynecol Oncol, 2018, 150(2): 282-287.
|